Osiris Therapeutics (OSIR) researches, develops, manufactures, markets, and distributes regenerative medicine products.
OSIR products include Grafix, a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns; BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery; and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects.
Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
September 10, 2010
Court of Appeal Stay Drives Stem Cell Stocks
August 12, 2010
Q2/10 Results, Osiris Therapeutics (OSIR)
July 21, 2010
Prochymal, Drug Submission Granted Priority Review by Health Canada (NASDAQ: OSIR)
June 11, 2010
OrthoCyte Corporation, New Subsidiary of BioTime (NYSE Amex: BTIM)
May 8, 2010
Q1/10 Results, Osiris Therapeutics (OSIR)
May 7, 2010
Osiris (OSIR) Resumes Enrollment in Stem Cell Trial for Crohn’s Disease Following Positive Interim Analysis
May 5, 2010
Osiris Therapeutics (OSIR) Receives Orphan Drug Designation for Stem Cell Type 1 Diabetes Treatment
April 26, 2010
Stem Cell Based Therapy Trial on Injured Heart Muscle Results
February 25, 2010
Q4/09 Results, Osiris Therapeutics (OSIR)
January 12, 2010
Cash, Partners, Advanced Trials; Osiris Therapeutics
35 companies, 1 interpreter!
Insight, foresight and recommendation
Osiris Therapeutics (OSIR) – Late Filing, SEC issues, officer crimminal indictments and yet another COO departs (number 5 in four years?). Started the year 2018 at $6.15, dived and jived to $6.95 by 2/1 and achieved $9.08 by 2/21. Once their "clean" it will be worth a near term topic until then "play" monopoly with the shares ... NO trust
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.